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Received June 3, 2015; accepted August 12, 2015AbstractBackground: Solanum nigrum is a herbaceous perennial plant, which is widely used in traditional medicine systems for its antioxidant, anti-
ulcerogenic, antitumorigenic, and anti-inflammatory characteristics. The purpose of this study was to investigate the protective effects of
S. nigrum against alcoholic liver damage in primary hepatocytes and mice, using glutathione S-transferase alpha 1 (GSTA1) as an indicator.
Methods: Primary hepatocytes were obtained by the inverse perfusion method improved on Seglen two-step perfusion in situ.
Results: In the presence of S. nigrum aqueous extracts (100 mg/mL), no hepatocytic damage was observed in cells treated with ethanol, compared
with the model group, and GSTA1 ( p < 0.01) was more sensitive than alanine aminotransferase and aspartate aminotransferase ( p < 0.05). Mice
that received S. nigrum aqueous extracts (150 mg/kg) with ethanol showed marked attenuation of ethanol-induced hepatotoxicity, as evidenced
by significant reductions of serum transaminases ( p < 0.01), and variation of hepatic oxidative indices ( p < 0.05) and GSTA1 ( p < 0.05),
compared with the model group and mice that received S. nigrum aqueous extracts (200 mg/kg). All the detection indexes were significantly
different ( p < 0.01) from those of the model group, and the protective effects were almost the same as that of the positive drug group.
Conclusion: These results suggested that S. nigrum has hepatoprotective effects against ethanol-induced injury both in vitro and in vivo, and can
protect the integrity of hepatocytes and thus reduce the release of liver GSTA1, which contributes to improved liver detoxification.
Copyright © 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Solanum nigrum (SN) is a species in the family Solanaceae,
native to Eurasia and introduced in America and Australia.1 It
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).traditional medicine systems for its antioxidant, anti-
ulcerogenic, antitumorigenic, and anti-inflammatory charac-
teristics.2 The plant has two significant alkaloids, solamargine
and solasonine, that produce carbohydrate glycone solasodine,
which is bioactive and in great demand in the pharmaceutical
industry.
Alcoholic liver damage is one of the most common hepatic
injuries worldwide. However, ethanol abuse and dependence
are becoming increasingly more serious and are presently a
topic of significant discussion associated with liver injury.3
Excessive consumption of ethanol can cause a series of he-
patic injuries, contributing to the development of alcoholicsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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and inflammation in the liver, leading to cirrhosis and hepa-
tocellular carcinoma.4 Progression of alcoholic liver diseases
is a multifactorial process, which involves a number of ge-
netic, nutritional, and environmental factors.5 Presently, there
is substantial evidence that oxidative stress is involved in the
pathogenesis and progression of liver injuries.6 Ethanol intake
increases the production of free radicals or reactive oxygen
species and causes oxidative stress by compromising the
antioxidant defense system.7
Glutathione S-transferases (GSTs) are widely used Phase II
drug-metabolizing enzymes that have the function of detoxifi-
cation in humans and animals. They are the most important part
of the antioxidant defense system in an organism, contributing to
the resistance against attacks of electrophilic substances and
catalyzing the reaction of exogenous chemicals to protect or-
ganisms.8 GSTs are usually divided into eight superfamilies,
alpha (A), kappa (K), mu (M), pi (P), sigma (S), theta (T), zeta
(Z), and omega (O), where the dominant component in the
human liver is alpha class [alpha-GST (GSTA)].9 GSTA is
encoded by a P12 gene cluster located in chromosome 6, which
contains five subunits (GSTA1eA5). GSTalpha 1 (GSTA1) is a
predominant member of the GSTA family10 and accounts for
65e75% of the total GSTs in the human liver. It plays an
important role in the antioxidative defense system, which can
catalyze many xenobiotics such as carcinogens, environmental
toxins, and certain drugs; it can also combine with glutathione
(GSH), promoting its degradation in the cells to remove and
protect the body.11With some efficacy, therefore, GSTA1 can be
used as a marker of liver injury. The changes of GSTA1 can be
detected at a low level during the early stage of acute hepatic
injury, and GSTA1 is a more sensitive and accurate indicator
than alanine aminotransferase (ALT).12
The present study aimed to investigate whether SN actually
has hepatoprotective effects against ethanol-induced hepatic
injury in vivo and in vitro, and further explore the role of
GSTA1 in liver detoxification as adjusted by SN. Regulation
of GSTA1 might aid in the prevention of hepatopathy and the
development of new drugs.
2. Methods2.1. ReagentsThe ethanol used in our study was purchased from the
Shanghai Chemical Reagent Factory (Shanghai, China). Type
IV collagenase, dimethyl sulfoxide, insulin, transferrin, hep-
arin, dexamethasone, and trypan blue were purchased from the
Sigma Chemical Co. (St Louis, MO, USA). GSTA1 detection
kit was purchased from American Rapidbio Company (RB;
23830 Arminta Street, West Hills, CA 91304, USA). SN and
silymarin were purchased from Harbin Jiacheng Dispensary
(Harbin, China). The detection kits of ALT, aspartate amino-
transferase (AST), malondialdehyde (MDA), superoxide dis-
mutase (SOD), GSH, and glutathione peroxidase (GSH-Px)
were obtained from the Nanjing Jiancheng Institute of
Biotechnology (Nanjing, China).2.2. Primary hepatocyte extraction and cultureThe liver of mice was rinsed and digested by the use of the
inverse perfusion method improved on Seglen two-step
perfusion in situ. After washing three times with Hank's
balanced salt solution, the liver was put into emundans culture
medium to end the digestion and extract cells gently with
tweezers. The hepatocytes were mixed fully with adherent
culture medium after filtration and centrifugation (500 rpm, 3
minutes). The number and survival rate of hepatocytes were
calculated after a trypan blue dyeing experiment. The hepa-
tocytes were seeded to a culture plate containing 24 wells
(5  104 cells/well) with rat tail collagen under the conditions
of 5% CO2 and 37
C for 6 hours, and then the nonadherent
hepatocytes were discarded along with the culture fluid. The
adherent culture medium was replaced with a growing culture
medium without serum, after which the growing culture me-
dium was substituted with the same culture medium after 24
hours.2.3. Animals and treatmentAdult male Kunming mice (18e22 g body weight) were
obtained from the Central Laboratory of Harbin Pharmaceu-
tical Group Co., Ltd (Harbin, Heilongjiang Province, China).
The animals were housed in a controlled environment under
standard conditions at a temperature of 20 ± 2C and a relative
humidity of 40e60%; they were allowed free access to food
(standard mice pellets) and water, and were acclimatized for at
least 1 week prior to use. All procedures involving animals
complied with the China National Institutes of Healthy
Guidelines for the Care and Use of Laboratory Animals.2.4. Preparation of SN aqueous extractsThe powder of SN (800 g) was dipped into 5000 mL water
for 30 minutes, and then extracted continuously for 40 minutes
at 100C to remove most of the colored materials, oligosac-
charides, and small-molecule compounds. The supernatant
was thereafter concentrated using a rotatory evaporator at
90C and dried by a vacuum drying oven at 70C to afford SN
aqueous extracts 185 g. The SN aqueous extracts accounted
for 23% of the original herb of Solanum nigrum.2.5. Hepatoprotective activities against ethanol-induced
cytotoxicityThe hepatocytes were randomly divided into five groups
(n ¼ 6): control group, ethanol model group, high-
concentration group of SN aqueous extracts (SN-H, 100 mg/
mL), middle-concentration group of SN aqueous extracts (SN-
M, 75 mg/mL), and low-concentration group of SN aqueous
extracts (SN-L, 50 mg/mL), respectively. The control and
ethanol model groups were treated with an equal volume of
culture medium. After 12 hours, we replaced the culture me-
dium, and each group was administered the culture medium
with 100 mmol/L ethanol except for the control group. After
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ALT, AST, and GSTA1; additionally, the hepatocytes were
collected for the determination of MDA, SOD, and GSH.2.6. Hepatoprotective activities against ethanol-induced
acute hepatic injuryForty-eight mice were randomly divided into six groups
(n ¼ 8): control group, ethanol model group, high-dose group
of SN aqueous extracts (SN-H, 200 mg/kg), middle-dose
group of SN aqueous extracts (SN-M, 150 mg/kg), low-dose
group of SN aqueous extracts (SN-L, 100 mg/kg), and posi-
tive drug group, respectively. The positive drug group was
administered 200 mg/kg silymarin, while the control and
ethanol model groups were given an equal volume of physi-
ological saline. Each group received the appropriate vehicle
daily by gavage for 7 days, and then was administered 50%
ethanol (14 mL/kg body weight) except for the control group.
After 8 hours, the serum was collected for the determination of
ALT, AST, and GSTA1, and the liver tissues were collected for
determination of MDA, SOD, GSH, GSH-Px, and GSTA1.
Subsequently, the liver tissues were preserved in 10% formalin
for histopathological analysis.2.7. Determination of indexesALT, AST, MDA, SOD, GSH, and GSH-Px were deter-
mined using detection kits according to the manufacturer's
instructions.2.8. Determination of GSTA1 content by enyzyme-linked
immunosorbent assayGSTA1 content was detected using the Mouse Glutathione S
Transferase Alpha1 (GSTA1) ELISA Kit (American Rapidbio
Company), which used Purified Mouse GSTA1 to coat micro-
titer plate wells, to make a solid-phase antibody. The procedure
was routinely performed according to the manufacturer's
instructions. The antibody had been diluted 500-fold and the
liver samples were diluted fivefold. According to the reportedFig. 1. Changes in ALT and AST activities in hepatocyte culture supernatant. Value
compared to the model group. *p < 0.05 and **p < 0.01 compared to the contro
Control ¼ control group; Model ¼ ethanol model group; SD ¼ standard deviatio
L ¼ group administered with S. nigrum aqueous extracts at a dose of 50 mg/mL; SN
mL. The significance of * in the footnotes means comparing with the control groumethod, the content of GSTA1 was determined by the color re-
action that produces a yellow complex with maximum absorp-
tion at 450 nm. A quantitative measure of GSTA in the sample
was calculated using the generated standard curve, and the
limits of quantification were determined to be 0.7e125 ng/mL.
All values were normalized by the total protein concentration of
the same sample.2.9. Histopathological analysisFormalin-fixed specimens were embedded in paraffin and
sectioned at 5 mm thickness, according to the routine proce-
dure. After hematoxylin and eosin staining, the slides were
observed for conventional morphological evaluation under a
light microscope and photographed at 400 magnification.2.10. Statistical analysisValues were expressed as mean ± standard deviation, and
statistical significance was determined by one-way analysis of
variance using the SPSS software 19.0 (SPSS, Inc., Chicago,
IL, USA). The Tukey's multiple comparison test in post hoc
multiple comparisons was used to examine the statistical
significance ( p < 0.05 and p < 0.01) between groups.
3. Results3.1. Protective effects of SN against ethanol-induced
hepatic injury in vitro
3.1.1. ALT and AST activities in hepatocyte culture
supernatant
Compared with the control group, ALT and AST activities
in the model group increased significantly ( p < 0.01), which
indicated that the model was replicated successfully. When
treated by the high-concentration SN aqueous extracts
(100 mg/mL), ALT and AST activities decreased markedly
( p < 0.05) compared with the model group. The results of
ALT and AST activities in hepatocyte culture supernatant are
presented in Fig. 1.s are expressed as mean ± SD in each group; n ¼ 6. #p < 0.05 and ##p < 0.01
l group. ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
n; SN-H ¼ group administered with S. nigrum at a dose of 100 mg/mL; SN-
-M ¼ group administered with S. nigrum aqueous extracts at a dose of 75 mg/
p and # means comparing with the model group.
Fig. 2. Changes in GSTA1 content in hepatocyte culture supernatant. Values
are expressed as mean ± SD in each group; n ¼ 6. #p < 0.05 and ##p < 0.01
compared to the model group. *p < 0.05 and **p < 0.01 compared to the
control group. Control ¼ control group; GSTA1 ¼ glutathione S-transferase
alpha 1; Model ¼ ethanol model group; SD ¼ standard deviation; SN-
H ¼ group administered with S. nigrum at a dose of 100 mg/mL;
SN-L ¼ group administered with S. nigrum aqueous extracts at a dose of
50 mg/mL; SN-M ¼ group administered with S. nigrum aqueous extracts at a
dose of 75 mg/mL.
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MDA, SOD, and GSH in the model group were signifi-
cantly different ( p < 0.01) from those of the control group,
which indicated that the model was replicated successfully.
When treated by the high-concentration SN aqueous extracts
(100 mg/mL), MDA decreased markedly ( p < 0.05), and SOD
and GSH increased markedly ( p < 0.05) compared with the
model group. The results of MDA, SOD, and GSH in hepa-
tocytes are presented in Table 1.
3.1.3. GSTA1 content in hepatocyte culture supernatant
The GSTA1 content of the model group increased signifi-
cantly ( p < 0.01) compared with that of the control group,
which indicated that the model was successfully replicated.
Compared with the model group, however, GSTA1 content
decreased markedly ( p < 0.05) in SN-M and significantly
( p < 0.01) in SN-H, which was more sensitive than ALT and
AST ( p < 0.05). When treated by the high-concentration SN
aqueous extracts (100 mg/mL), the GSTA1 content was close
to the control group and consistent with other detection in-
dexes. The results of GSTA1 content in hepatocyte culture
supernatant are presented in Fig. 2.3.2. Protective effects of SN against ethanol-induced
hepatic injury in vivo
3.2.1. ALT and AST activities in the serum
Compared with the control group, ALT and AST activ-
ities of the model group increased significantly ( p < 0.01),
which indicated that the model was replicated successfully.
Serum ALT and AST activities in SN-M and SN-H
decreased significantly ( p < 0.01) compared with those in
the model group. The prevention effects were almost the
same as that in the positive drug group with a high dose of
SN aqueous extracts, 200 mg/kg, in treated animals. The
results of ALT and AST activities in the serum are presented
in Fig. 3.Table 1
Changes in MDA, SOD, and GSH in primary hepatocytes.
Group MDA SOD GSH
(nmol/mg protein) (U/mg protein) (mmol/g protein)
Control 1.05 ± 0.23 23.71 ± 2.67 8.64 ± 1.07
Model 1.97 ± 0.15## 16.90 ± 1.44## 5.98 ± 0.83##
SN-L 1.89 ± 0.14 17.57 ± 0.94 6.32 ± 0.80
SN-M 1.69 ± 0.13 19.09 ± 1.27 6.98 ± 0.65
SN-H 1.58 ± 0.12* 20.97 ± 2.06* 7.81 ± 0.99*
Values are expressed as the mean ± SD in each group; n ¼ 6.
#p < 0.05 and ##p < 0.01 compared to the model group.
*p < 0.05 and **p < 0.01 compared to the control group.
Control ¼ control group; GSH ¼ glutathione; MDA ¼ malondialdehyde;
Model ¼ ethanol model group; SD ¼ standard deviation; SN-H ¼ group
administered with S. nigrum at a dose of 100 mg/mL; SN-L ¼ group admin-
istered with S. nigrum aqueous extracts at a dose of 50 mg/mL; SN-M ¼ group
administered with S. nigrum aqueous extracts at a dose of 75 mg/mL;
SOD ¼ superoxide dismutase.3.2.2. MDA, SOD, GSH, and GSH-Px in the liver
MDA, SOD, GSH, and GSH-Px of the model group were
significantly different ( p < 0.01) from those of the control
group, which indicated that the model was reproduced suc-
cessfully. Compared with the model group, MDA decreased
markedly in SN-M ( p < 0.05) and SN-H ( p < 0.01), whereas
SOD, GSH, and GSH-Px increased markedly ( p < 0.05) in
SN-M and decreased significantly ( p < 0.01) in SN-H. The
prevention effects were almost the same as that in the positive
drug group, with a high dose of SN aqueous extracts, 200 mg/
kg, in treated animals. The results of MDA, SOD, GSH, and
GSH-Px in the liver are presented in Table 2.
3.2.3. GSTA1 contents in the serum and liver
GSTA1 contents in the serum and liver in the model group
were significantly different ( p < 0.01) from those in the
control group, which indicated that the model was reproduced
successfully. Serum GSTA1 in SN-M and SN-H decreased
significantly ( p < 0.01) compared with the model group
(Fig. 4A). Liver GSTA1 increased markedly ( p < 0.05) in SN-
M and decreased significantly ( p < 0.01) in SN-H (Fig. 4B).
The prevention effects were almost the same as that in the
positive drug group with a high dose of SN aqueous extracts,
200 mg/kg, in treated animals, which was consistent with
other detection indexes. The results of GSTA1 contents in the
serum and liver are presented in Fig. 4.
3.2.4. Histopathological analysis
The round vacuoles, inflammatory cell infiltration, and
hepatocyte spotty necrosis are shown in the ethanol model
group. The slight inflammation of hepatocytes in the positive
drug group is reduced, and the hepatic lobules are more clear
and complete than those in the model group. The degree of
injury of the high-dose group of SN aqueous extracts, 200 mg/
kg, is obviously lower than that of the model group, which is
close to the positive drug group.
Fig. 3. Changes in ALT and AST activities in the serum of mice with ethanol-induced acute hepatic injury. Values are expressed as mean ± SD in each group; n ¼ 8.
#p < 0.05 and ##p < 0.01 compared to the model group. *p < 0.05 and **p < 0.01 compared with the control group. ALT ¼ alanine aminotransferase;
AST ¼ aspartate aminotransferase; Control ¼ control group; Model ¼ ethanol model group; Positive ¼ group administrated with silymarin at a concentration of
200 mg/kg; SD ¼ standard deviation; SN-H ¼ group administered with S. nigrum at a dose of 100 mg/mL; SN-L ¼ group administered with S. nigrum aqueous
extracts at a dose of 50 mg/mL; SN-M ¼ group administered with S. nigrum aqueous extracts at a dose of 75 mg/mL.
Table 2
Changes in MDA, SOD, GSH, and GSH-Px in the liver.
Group MDA SOD GSH GSH-Px
(nmol/mg protein) (U/mg protein) (mmol/g protein) (U/mg protein)
Control 6.96 ± 1.03 92.47 ± 8.34 14.97 ± 1.15 310.98 ± 31.62
Model 10.45 ± 0.88## 59.87 ± 9.32## 9.52 ± 1.87## 197.88 ± 26.82##
SN-L 9.88 ± 0.50 63.90 ± 5.64 10.15 ± 1.16 207.27 ± 24.09
SN-M 8.70 ± 0.63* 77.49 ± 4.41* 12.96 ± 0.97* 255.53 ± 40.54*
SN-H 7.88 ± 0.55** 84.74 ± 5.23** 13.78 ± 1.07** 299.60 ± 34.73**
Positive 7.31 ± 0.93** 89.89 ± 9.46** 14.09 ± 1.74** 302.18 ± 27.78**
Values are expressed as the mean ± SD in each group; n ¼ 8.
#p < 0.05 and ##p < 0.01 compared to the model group.
*p < 0.05 and **p < 0.01 compared to the model group.
Control ¼ control group; GSH ¼ glutathione; GSH-Px ¼ glutathione peroxidase; MDA ¼ malondialdehyde; Model ¼ ethanol model group; Positive ¼ group
administrated with silymarin at a concentration of 200 mg/kg; SD ¼ standard deviation; SN-H ¼ group administered with S. nigrum at a dose of 100 mg/mL;
SN-L ¼ group administered with S. nigrum aqueous extracts at a dose of 50 mg/mL; SN-M ¼ group administered with S. nigrum aqueous extracts at a dose of
75 mg/mL; SOD ¼ superoxide dismutase.
Fig. 4. Changes in GSTA1 contents in the (A) serum and (B) liver of mice with ethanol-induced acute hepatic injury. Values are expressed as mean ± SD in each
group; n ¼ 8. #p < 0.05 and ##p < 0.01 compared to the model group. *p < 0.05 and **p < 0.01 compared to the control group. Control ¼ control group;
GSTA1 ¼ glutathione S-transferase alpha 1; Model ¼ ethanol model group; Positive ¼ group administrated with silymarin at a concentration of 200 mg/kg;
SD ¼ standard deviation; SN-H ¼ group administered with S. nigrum at a dose of 100 mg/mL; SN-L ¼ group administered with S. nigrum aqueous extracts at a
dose of 50 mg/mL; SN-M ¼ group administered with S. nigrum aqueous extracts at a dose of 75 mg/mL.
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SN is one of the medicinal herbs that belong to the family
“Solanaceae” and has been used traditionally to treat various
ailments.13 A glycoprotein isolated from SN has been shownto have antioxidative activity14; antioxidant activity was
shown to be correlated to polyphenol content, signifying that
phenolic compounds are probably responsible for this prop-
erty. Hence, the main mode of conferred hepatoprotection
appears to be through control of oxidative damage and free
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periodic, antiphlogistic, diuretic, emollient, febrifuge,
narcotic, purgative, and sedative.16 In this experiment, we
selected SN as a preventive drug and studied its hep-
atoprotective effects, using primary hepatocytes and animal
models challenged with ethanol.
Previous findings by our group have established three acute
hepatic injury models induced by carbon tetrachloride, acet-
aminophen, and ethanol in mice, and have proved that GSTA1,
one of the main Phase II drug-metabolizing enzymes and that
which can catalyze many xenobiotics, was detected at low
concentrations during the early stages of acute hepatic injury.
Thus, GSTA1 is a more sensitive and more accurate indicator
than ALT,10 and the changes of GSTA1 in this study provide
further evidence supporting this viewpoint.
Primary hepatocytes are the golden standards for studying
hepatotoxicity of drugs in vitro,17 which maintain both Phase I
and Phase II metabolic activities as well as uptake transporter
activity.18 Unlike immortalized cell lines, freshly isolated
primary hepatocytes in vitro retain liver-specific functions
related to drug metabolism.19 In this experiment, primary
hepatocytes were obtained from the liver of mice by the in-
verse perfusion method improved on Seglen two-step perfu-
sion in situ. Three doses of SN aqueous extracts were treated
in the primary hepatocytes to study the hepatoprotective ef-
fects. In the presence of SN aqueous extracts (100 mg/mL), no
hepatocytic damage was observed in the cells treated with
ethanol, compared with the model group; GSTA1 was more
sensitive than ALT and AST. These results are consistent with
our previous findings. In primary hepatocytes, with a treatment
does, 100 mg/mL, SOD activity and GSH content increased
markedly, while MDA content decreased markedly, which
suggested that no significant cytotoxic effects were found at a
high dose of SN. Therefore, SN plays an important role in
antioxidant activity and also has the effect of reducing lipid
peroxidation injury. Thus, we estimated that SN has obvious
hepatoprotective effects against ethanol-induced injury at a
cellular level and the optimal dose is 100 mg/mL.
An acute hepatic injury model induced by ethanol in mice
was replicated successfully according to our previous studies.
Three doses of SN aqueous extracts were given to the animals,
using silymarin as a reference, which is an antihepatotoxic
substance that has been investigated as a supportive treatment
for liver damage from various chemicals or toxins.20 In vivo,
mice that received SN aqueous extracts (150 mg/kg) with
ethanol showed marked prevention of ethanol-induced hepa-
totoxicity, as evidenced by the significant reductions of serum
transaminases (ALT and AST), and variation of hepatic
oxidative indexes (MDA, SOD, GSH, and GSH-Px) and
GSTA1 compared with the model group. Furthermore, for
mice that received SN aqueous extracts (200 mg/kg), all the
detection indexes were significantly different from those of the
model group, and the prevention effects were almost the same
as those in the positive drug group. These results suggested
that SN can remove harmful free radicals, block the magnified
chain reaction of free radicals, and maintain hepatocellular
redox homeostasis, thus protecting the integrity ofhepatocytes. Consequently, we estimated that SN has obvious
hepatoprotective effects against ethanol-induced acute injury
in mice and the optimal dose is 200 mg/kg.
GSTA1 is highly expressed in the normal liver,21 and its
protein plays an important role in the body's antioxidant system,
which catalyzes the conjugation of GSH with carcinogens,
drugs, toxins, or products of oxidative stress.22 In this study,
animals were administered SN, whereafter serum GSTA1
content decreased significantly at doses of 150 mg/kg and
200 mg/kg, while liver GSTA1 content increased significantly
at doses of 150 mg/kg and 200 mg/kg. These results indicated
that SN has obvious hepatoprotective effects against ethanol-
induced acute injury. Simultaneously, it protects the integrity
of hepatocytes and thus reduces the release of liver GSTA1,
which contributes to an improvement in liver detoxification.
Noticeably, the administration of SN at a dose of 200 mg/kg/
d almost prevented liver dysfunctions from alcoholic toxicity.
In conclusion, the changes of all the indexes suggested that
GSTA1 is a more sensitive indicator of hepatotoxicity. SN has
hepatoprotective effects against ethanol-induced hepatic injury
both in vitro and in vivo, and it may be an important free
radical scavenger of hepatocytes, protecting the integrity of
hepatocytes to reduce the release of liver GSTA1; then GSTA1
could participate in the oxidative stress and protect the liver
against injuries. Therefore, GSTA1 plays an important role in
preventing liver dysfunction from alcoholic toxicity, and the
regulation of GSTA1 might aid in the prevention of hepatop-
athy and development of new drugs.
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